Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims correctly identify Cosentyx as an IL-17A–targeting monoclonal antibody but partially misstate dosing scope and inaccurately assert interactions or vaccine guidance not present in the label. Several MMR-related vaccine claims are not supported by the FDA-approved Cosentyx labeling; the label cautions about live vaccines and vaccination considerations in patients on biologics, but does not endorse CDC statements or guarantee no interactions.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A).
Cosentyx labeling: Mechanism of Action (IL-17A)
Unsupported Statements
The MMR vaccine is a live, attenuated vaccine that contains weakened forms of the measles, mumps, and rubella viruses.
Labeling provided does not detail MMR vaccine content; not supported by the Cosentyx labeling in this prompt.
The MMR vaccine is administered in two doses, with the first dose typically given at 12-15 months of age and the second dose at 4-6 years of age.
Labeling in this prompt does not specify MMR dosing schedule.
The MMR vaccine has a vaccine efficacy of 93% or higher.
Labeling in this prompt does not specify MMR vaccine efficacy.
Cosentyx is administered via subcutaneous injection every 4 weeks.
Labeling indicates loading doses at Weeks 0–4 with maintenance every 4 weeks; the claim omits loading doses.
The CDC states there is no known interaction between the MMR vaccine and Cosentyx.
Labeling does not provide a CDC statement about MMR interactions; this is not supported by the Cosentyx label in this prompt.
A study in the Journal of Clinical Rheumatology... found psoriasis flare after MMR with Cosentyx due to vaccine activation.
Labeling does not reference this study or a vaccine-triggered flare specific to MMR and Cosentyx.
DrugPatentWatch.com states there are currently no known interactions between the MMR vaccine and Cosentyx.
Labeling guidance should rely on FDA labeling; external sources are not a substitute for label information.
Dr. Mark Lebwohl states there is no known interaction between the MMR vaccine and Cosentyx, but monitoring is essential.
Personal statements are not substitute for FDA-labeled vaccination guidance.
Healthcare professionals should exercise caution when administering vaccines to patients taking biologics like Cosentyx.
Labeling supports cautious vaccination decisions in patients on biologics; this statement is broadly aligned.
Patients should be monitored for any changes in symptoms after receiving the vaccine, and healthcare professionals should be prepared to adjust treatment plans as needed.
Labeling provides general vaccination considerations but does not specify post-vaccine monitoring or treatment adjustments for Cosentyx.
There is no known interaction between the MMR vaccine and Cosentyx, but there is potential for temporary increases in psoriasis symptoms after the MMR vaccine.
Labeling does not support a blanket 'no interaction' claim and does not document a vaccine-triggered psoriasis flare.
Healthcare professionals should be aware of the potential for temporary increases in psoriasis symptoms after receiving the MMR vaccine and be prepared to adjust treatment plans as needed.
Labeling does not specify psoriasis symptom changes post-MMR vaccination.
It is possible to receive the MMR vaccine if you have psoriasis treated with Cosentyx, but you should be monitored for any changes in symptoms after receiving the vaccine.
Live vaccines are generally avoided during Cosentyx treatment per label; this statement could mislead about eligibility.
You can receive other vaccines while receiving Cosentyx, but you should consult with your healthcare professional before receiving any vaccine.
Labeling allows vaccination decisions with caution; it does not specify vaccine type and may be imprecise without distinguishing live vs inactivated vaccines.
If you experience increased psoriasis symptoms after receiving the MMR vaccine, contact your healthcare professional for guidance on adjusting your treatment plan.
Labeling does not provide post-MMR-specific management guidance for psoriasis.
It is possible to receive the MMR vaccine if you have psoriasis treated with Cosentyx, but you should be monitored for any changes in symptoms after receiving the vaccine.
Reiterates permissive stance toward MMR with Cosentyx without acknowledging live vaccine considerations in the label.
You can receive other vaccines while receiving Cosentyx, but you should consult with your healthcare professional before receiving any vaccine.
While vaccination decisions with caution are described in the label, the statement should specify inactivated vaccines vs live vaccines to be precise.
Contradictions
Important Omissions
Explicit guidance from the label on live vaccines vs inactivated vaccines in the context of Cosentyx; loading-dose details for Cosentyx dosing (Weeks 0-4) not captured by the single-dose claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims do not introduce new safety concerns beyond the label's immunization cautions; however, misinformation about vaccine interactions could mislead safety decisions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overstatements about vaccine interactions and MMR-specific vaccine claims not supported by the Cosentyx label; dosing claim omits loading-dose details.
Suggested Improvement
Limit statements to label-supported information; specify that Cosentyx dosing for adults includes loading doses at Weeks 0–4 with maintenance every 4 weeks; emphasize live vaccine avoidance with Cosentyx and provide vaccination guidance consistent with label.